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Abstract
Fanconi anemia (FA) is an inherited disorder characterized by defective DNA repair and cellular
sensitivity to DNA crosslinking agents. Clinically, FA is associated with high risk for marrow
failure, leukemia and head and neck squamous cell carcinoma (HNSCC). Radiosensitivity in FA
patients compromises the use of total-body irradiation for hematopoietic stem cell transplantation
and radiation therapy for HNSCC. A radioprotector for the surrounding tissue would therefore be
very valuable during radiotherapy for HNSCC. Clonogenic radiation survival curves were
determined for pre- or postirradiation treatment with the parent nitroxide Tempol or JP4-039 in
cells of four FA patient-derived cell lines and two transgene-corrected subclonal lines. FancG–/–
(PD326) and FancD2–/– (PD20F) patient lines were more sensitive to the DNA crosslinking agent
mitomycin C (MMC) than their transgene-restored subclonal cell lines (both P < 0.0001).
FancD2–/– cells were more radiosensitive than the transgene restored subclonal cell line (ñ = 2.0 ±
0.7 and 4.7 ± 2.2, respectively, P = 0.03). In contrast, FancG–/– cells were radioresistant relative to
the transgene-restored subclonal cell line (ñ = 9.4 ± 1.5 and 2.2 ± 05, respectively, P = 0.001).
DNA strand breaks measured by the comet assay correlated with radiosensitivity. Cell lines from a
Fanc-C and Fanc-A patients showed radiosensitivity similar to that of Fanc-D2–/– cells. A
fluorophore-tagged JP4-039 (BODIPY-FL) analog targeted the mitochondria of the cell lines.
Preirradiation or postirradiation treatment with JP4-039 at a lower concentration than Tempol
significantly increased the radioresistance and stabilized the antioxidant stores of all cell lines.
Tempol increased the toxicity of MMC in FancD2–/– cells. These data provide support for the
potential clinical use of JP4-039 for normal tissue radioprotection during chemoradiotherapy in
FA patients.
INTRODUCTION
Fanconi anemia (FA) is an autosomal recessive disorder characterized by dysfunctional
DNA repair and increased incidence of aplastic anemia, myelodysplasia, acute myeloid
leukemia, and epithelial malignancies (1–4), presenting at unusually early ages (2, 5–9). The
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overall median survival is 24 years (3, 4). FA patients who survive to their early adulthood
years are 50 times more likely to develop solid tumors, particularly head and neck squamous
cell carcinoma (HNSCC), compared to the general population (1, 4, 7, 10, 11). Thus FA
patients may require radiotherapy for appropriate management (7, 8) despite their intrinsic
cellular radiosensitivity (4–9, 12, 13).
Cells from FA patients display sensitivity to DNA crosslinking agents such as mitomycin C
(MMC), cisplatin and diepoxybutane (9, 12, 14, 15). Chromosomal breakage in FA cells in
response to alkylating agents is also frequent (9). The DNA repair dysfunction in FA has
been attributed to mutations in one or more of 13 FA complementation groups (5). In the
normal cellular response to DNA damage, FA proteins A, B, C, E, F, G, L and M form a
nuclear complex that functions as a ubiquitin ligase, with FancL as its catalytic subunit for
ubiquitination (5, 16). The L subunit then monoubiquinates the FancD2 and FancI proteins
(17–19). Activated FancD2-FancI protein complex subsequently colocalizes with FA
proteins (FancD1, FancN and FancJ) and other DNA repair proteins, including NBS1, to
form nuclear foci that mediate DNA repair (5, 17–19).
Therapeutic approaches to the hematological defects in FA include allogeneic hematopoietic
stem cell transplantation (20, 21). The problem of increased graft failure due to the need to
use decreased doses of cyclophosphamide and total-body radiation in the preparative
regimen of FA patients has been largely overcome by the addition of fludarabine (22).
However, the adequacy of any transplantation regimen for FA patients with myelodysplasia
or leukemia remains an issue (13–15, 20, 21, 23). Moreover, both young and older adult FA
patients are developing HNSCC diagnosed either primarily or after hematopoietic stem cell
transplantation. Most are treated with surgery alone, potentially contributing to the multiple
primary cancers and relatively worse 2-year survival in comparison to non-FA HNSCC
patients (1, 4, 7). In the cases where radiation therapy is used, the reduced dose may
compromise tumor control and clinical outcome. A normal tissue radioprotective agent
would be useful, but it must be safe in FA patients, not all of whom are equivalently
radiosensitive (13–15, 23). In the present studies, we tested the mitochondrial targeted GS-
nitroxide, JP4-039, for radiobiological effects on cell lines derived from four patients and in
two FA patients compared to their transgene restored subclonal lines.
METHODS
Cell Lines
The Fanc-A patient cell line (OHSU-974) and Fanc-C patient cell line (VU1131)(52) were a
gift from Dr. Hans Joenje, Vrige University Medical Center, Amsterdam, The Netherlands.
The FA patient-derived cell lines, FancG–/– (PD326) and FA transgene-restored FancG
subclone, were a gift from Dr. Christopher Bakkenist (University of Pittsburgh School of
Medicine, Pittsburgh, PA). The FancD2–/– (PD20F) patient and transgene-restored FancD2
subclonal lines were a gift from Dr. Alan D'Andrea (Dana Farber Cancer Institute, Boston
MA). The latter two cell lines have been described previously, including functional
diagnosis by in vitro MMC sensitivity and its correction by transgene insertion (17, 24, 25).
FancG–/– (PD326) and FancG transgene cells were maintained in a high-humidity incubator
at 37°C and 95% air/5% CO2. Cells were cultured in Dulbecco's modified Eagle medium
(DMEM) with 15% fetal bovine serum (FBS),1% L-glutamine and 1% penicillin-
streptomycin (26) in T-75 flasks. FancD2–/– (PD20F) and FancD2 transgene-restored cells
were maintained in the same incubator conditions but were cultured in RPMI 1640 medium
with 15% FBS, 1% L-glutamine and 1% penicillin-streptomycin.
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Assay for Cell Line Mitomycin C Sensitivity
FA and FA transgene-restored cells were grown in T-25 flasks. When the cells were 50%
confluent, MMC was added in concentrations between 0 and 100 ng/ml daily for 3 days.
Cells were then trypsinized and plated in 4-well plates at 1,000 cells per 15 ml. Eight days
later, colonies of greater than 50 cells were stained with crystal violet solution and counted.
Results are the means ± SEM of three separate experiments with at least six plates per point.
Radiosensitivity of FA and FA Transgene-Restored Cell Lines
Radiosensitivity of each FA and FA transgene-corrected fibroblast line was measured using
a clonogenic colony-forming assay (27). Cells in logarithmic phase growth were irradiated
with doses ranging from 0 to 8 Gy (J. L. Shepherd Mark V Irradiator, 70 cGy/min), then
plated in Linbro 4-well tissue culture plates (MP Biomedicals, LLC, Solon, OH) at
concentrations of 125, 250 or 1000 cells per 4.0 ml per well. Eight days later colonies of >50
cells were stained with crystal violet solution and counted using a GelCount cell colony
counter (Oxford Optronix, Oxford, UK). The data were analyzed using linear-quadratic or
single-hit, multitarget models (28, 29). Each experiment was repeated at least three times on
three different days. The comparative protection and mitigation assay for JP4-039 and
Tempol used comet assays as described (30, 31).
Synthesis of a Fluorophore-Tagged JP4-039 Analog
The detection of JP4-039 in cell tissue samples previously used ESR and MS methods (32,
33). For additional biological studies and to investigate the ability of these nitroxides to
localize in the mitochondria, we desired a more direct fluorescence-based visualization and
selected a BODIPY-FL® fluorophore for this purpose (34). An analog of JP4-039 with a
BODIPY-FL® label in place of the N-Boc group was synthesized using a de novo synthesis
approach (35). The direct synthesis of this labeled derivative from JP4-039 failed, since,
after the Boc group of JP4-039 was successfully removed with HCI, treatment of the free
amine with the N-hydroxysuccinimide activated ester of BODIPY-FL® (BODIPY-FL-NHS)
provided an 83:17 mixture of the undesired bis-coupling product and the desired
EMF338-008.
To avoid this unwanted side product, we intended to attach the BODIPY-FL® label to the
alkene peptide isostere scaffold prior to addition of the TEMPO group. Accordingly, the
carboxylic acid was protected as the methyl ester. Removal of the Boc-protecting group with
trifluroacetic acid (TFA) followed by coupling to BODIPY-FL-NHS provided the conjugate
in 82% yield. Saponification of the methyl ester under standard basic conditions resulted in
extensive decomposition; therefore, pig liver esterase (PLE) in acetone/pH 7 phosphate
buffer was used to effect a chemoselective transformation. Coupling of the resulting acid to
4-amino-tempo (4-AT) provided the desired BODIPY-FL®-labeled compound JP4-039-
BODIPY (EMF338-008) in 56% yield over two steps (35).
Mitochondrial Localization of Fluorochrome-Labeled JP4-039 (BODIPY)
Fanc-D2 and FD20F cells were grown on glass cover slips for staining with MitoTracker
Red (Molecular Probes-Invitrogen, Eugene, OR) and JP4-039-BODIPY. The cover slips
were incubated with 10 μM JP4-039-BODIPY and 100 μM MitoTracker for 15 min at 37°C.
The cells were washed with warm RPMI 1640 medium and fixed with 3.7%
paraformaldehyde. The cover slips were mounted with either Prolong Gold/DAPI
(Molecular Probes-Invitrogen) or gelvatol containing Hoechest and imaged using
fluorescence and confocal microscopy.
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Measurement of DNA strand breaks after irradiation was performed as described previously
(30, 31). Cells of the Fanc-D2, Fanc-G, PD20F and PD326 cell lines were irradiated to
either 0 or 6 Gy and incubated at room temperature for 10 min, at which time the cells were
rapidly chilled to 4°C to stop DNA repair. The cells were mixed in low melt agarose, and
500 cells were placed on the sample area of a CometSlide (Comet Assay 4250-050-K,
Travigen, Inc., Gaithersburg, MD). The slides were rapidly chilled to 4°C and kept in the
dark to prevent DNA repair. The slides were then placed in prechilled lysis solution and kept
at 4°C for 60 min followed by washing in neutral electrophoresis buffer for 30 min at 4°C
and electrophoresis at 21 V for 1 h at 4°C, then immersed in DNA precipitation solution for
30 min at room temperature, immersed in 70% ethanol for 30 min, and dried at 45°C for 15
min. The cells were then stained with SYBR Green 1 and examined under a fluorescence
microscope, and the comet tails for each of 150 cells were quantified using the Comet Assay
IV software.
Assays for Oxidative Stress Responses of Cell Lines to Radiation
The assay for intracellular glutathione stores using a Calbiochem Glutathione Assay Kit II
(EMB Serono, Inc., Rockland, MA) has been published previously (36, 37). Cells of the
Fanc-D2, Fanc-G, PD20F and PD326 cell lines were incubated for 1 h in JP4-039 (10 μM),
irradiated to 0, 2 or 6 Gy, and collected by centrifugation 24 h later. The cells were
homogenized in 50 mM phosphate buffer containing 1 mM EDTA and centrifuged at
10,000g for 15 min at 4°C. Protein levels were determined in each sample, 50 μl of each
sample was added to individual wells in a 96-well plate, and 150 μl of cocktail mix was
added to each well. Absorbance at 405 was determined 25 min later, and GSH concentration
was determined using the End Point Method.
GS-Nitroxide and Tempol Treatment Effects on Radiosensitivity and Mitomycin C
Sensitivity
Prior to or after irradiation or MMC addition, cells from each line were treated with 10 μM
JP4-039 or Tempol. These concentrations have been shown to be optimal for radiation dose–
response curves of human cells in vitro (27, 32). For protection experiments, drugs were
added 1 h before irradiation or 1 h before adding MMC. For mitigation experiments,
JP4-039 or Tempol was added immediately after irradiation. For MMC drug sensitivity,
Tempol or JP4-039 was also added once daily for 3 days; these cells were then grown in
nonsupplemented medium for an additional 5 days, and cell survival was scored on day 8.
Irradiated or MMC-treated cells were transferred to tissue culture plates for the colony assay
and at day 8 were stained using crystal violet solution. Colonies ≥ 50 cells were then
counted. MMC-treated cell-derived colonies were scored on day 8.
Statistics
For radiosensitivity, the D0 and ñ were calculated for each group using means ± SD.
Comparisons were made between any two groups with the two-sided two-sample t test. P ≤
0.05 was regarded as significant, and P values were adjusted for multiple comparisons. For
mitomycin C sensitivity, the data for number of colonies were summarized as means ± SD
for each group at each MMC dose. The number of colonies were log-transformed, and a
linear mixed model was fitted on the log-transformed data with group and MMC dose. Their
interaction term was fixed as an explanatory variable within each subject variable, MMC
dose, and used as a repeated measure. The F test was used to test for the significance of the
interaction between each JP4-039- or Tempol treated group relative to each MMC dose. A
significant interaction was defined as one showing a P < 0.05 in the MMC-induced decrease
in colony numbers between groups.
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FancG–/– and FancD2–/– Cell Lines are Sensitive to Mitomycin C
We first confirmed the diagnostic phenotype of the two FA patient cell lines. Comparison of
the MMC sensitivity of each FA patient cell line with its respective transgene-restored cell
line was carried out. FancG–/– (PD326) cells were more sensitive to MMC (P < 0.0001) than
was the transgene-restored FancG cell line (Fig. 1A). FancD2–/– (PD20F) cells were also
more sensitive to MMC (P < 0.0001) than the transgene-restored FancD2 cells (Fig. 1B).
These results confirm the diagnostic FA phenotype in both lines and their normalization by
restoration of the respective functional complementation genes (38).
Radiosensitivity of FA Patient and FA Transgene-Restored Cell Lines
We evaluated the radiosensitivity of each FA cell line and its transgene-restored subclonal
cell line. The FancG–/– (PD326) cell line was radioresistant relative to its respective
transgene-corrected line (Table 1). In contrast, the FancD2–/– (PD20F) cell line was
radiosensitive relative to its transgene restored line (Table 1). The Fanc-C and Fanc-A
patient cells were more like the Fanc-D2–/– line in radiation sensitivity (Table 2). These
results establish a clear heterogeneity in radiosensitivity between FA patient cell lines.
GS-nitroxide, JP4-039, Increases Radioresistance of Both FA Cell Lines and Transgene-
Restored Subline
The mitochondrial targeted GS-nitroxide drug JP4-039 or its parent non-mitochondrial
targeted nitroxide, Tempol, were added either before irradiation (protection) or after
irradiation (mitigation). Adding JP4-039 before irradiation increased the radioresistance,
shown as an increase in the ñ of FancG–/– (PD326) (P = 0.02) as well as transgene-restored
FancG cells (P = 0.002) (Table 1). Pretreatment with JP4-039 also increased the
radioresistance of FancD2–/– cells (PD20F), seen as an increase in D0 (P = 0.04), and the
transgene-restored subline FancD2, seen as an increase in ñ (P = 0.04) (Table 1).
In radiation mitigation experiments, JP4-039 added after irradiation increased the
radioresistance of both FancG–/– (PD326) and FancG transgene-restored cells, as shown by
an increase in ñ (P = 0.001 and 0.02, respectively) (Table 1). Tempol added after irradiation
also increased radioresistance (P = 0.001 and 0.01, respectively) (Table 1). When added
after irradiation, JP4-039 increased the radiation resistance of FancD2–/– (PD20F) and
FancD2 transgene-restored cells, as shown by an increase in ñ (P = 0.001 and 0.02,
respectively) (Table 1). Tempol was a less effective mitigator for FancD2–/– (PD20F) and
FancD2 cells (Table 1). Both Fanc-A–/– and Fanc-C–/– cells were protected and mitigated by
JP4-039 (Table 2).
JP4-039 Localization in Mitochondria Increases Effectiveness Compared to Tempol
We evaluated the importance of mitochondrial localization of JP4-039, comparing it to
Tempol. Table 3 shows greater radiation protection at lower concentrations of JP4-039
compared to Tempol. To confirm that mitochondrial localization was occurring, we targeted
a fluorochrome-labeled analogue of JP4-039. Figure 2 shows that fluorophore-labeled-
JP4-039 BODIPY but not the fluorophore alone (not shown) localized to mitochondria of
both Fanc-D2–/– (PD20F) and transgene-restored Fanc-D2 cells. JP4-039-BODIPY was as
effective as JP4-039 as a radioprotector and mitigator of Fanc-D2 cells (Table 4). Thus the
fluorochrome labeling did not abrogate the radioprotective capacity of JP4-039.
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JP4-039 Ameliorates Reduction of Glutathione by Radiation in Fanconi Anemia Cell Lines
To determine whether the radioprotective and mitigative capacity of JP4-039 was associated
with its function as a free radical scavenger, we used established assays for radiation-
mediated depletion of antioxidant stores (36). Table 5 shows that JP4-039 treatment
maintained high intracellular antioxidant stores after 2 Gy or 6 Gy irradiation.
JP4-039 Does Not Alter MMC Sensitivity of FA Patient Cell Lines
We tested the effects of JP4-039 and Tempol on the sensitivity of FA cell lines and
respective transgene-restored cell lines to MMC. As shown in Fig. 3, there was no
significant effect of JP4-039 or Tempol on the relative sensitivity of FancG–/– (PD326) or
FancG cell lines to MMC. However, Tempol increased the sensitivity of both FancD–/–
(PD20F) and FancD2 transgene-restored cells to MMC (P = 0.005 and 0.04) (Fig. 3).
Relative Radioresistance of Fanc-G–/– (PD326) Cells Correlates with Decreased Radiation-
Induced DNA Double-Strand Breaks
We measured DNA double-strand breaks after 6 Gy irradiation by a comet assay in Fanc-
G–/– (PD326) and Fanc-G cells compared to Fanc-D2–/– (PD20F) and Fanc-D2 transgene-
restored cells. The two cell lines with the most DNA strand breaks were the Fanc-D2–/–
(PD20F) and Fanc-G cells (Fig. 4), which were also more radiosensitive as determined by
clonogenic survival curve analysis.
Radiation survival curves demonstrated that the Fanc-D2 transgene-restored cells were more
radioresistant than PD20F cells. The nonirradiated PD20F cells also had more DNA double-
strand breaks than did the nonirradiated transgene-restored Fanc-D2 cells (P = 0.002).
Comet assay data demonstrated that PD20F cells had more DNA double-strand breaks after
6 Gy than did the Fanc-D2 gene-restored cells (P < 0.0001). Fanc-D2 cells were relatively
radioresistant compared to PD20F cells by clonogenic survival curve assay.
The comet assay data also agreed with the clonogenic radiation survival curve data for Fanc-
G and PD326 cells. Fanc-G cells had increased comet intensity after 6 Gy irradiation
compared to PD326 cells (P < 0.0001); however, in contrast to the Fanc-D2–/– (PD20F) and
transgene-restored cells, there was no significant difference between the unirradiated Fanc-G
and PD326 cells (P = 0.06).
DISCUSSION
Given the limitations that intrinsic radiosensitivity places on the tolerance for fractionated
external-beam radiotherapy (1, 4, 10, 11), there is increasing concern for the high incidence
of oral cavity and oropharyngeal cancers occurring both de novo (39) and in previously
transplanted FA patients (39). Recently available organ-specific radio-protective agents can
increase esophageal radiation tolerance in non-small-cell lung cancer patients (32, 33, 40)
and oral cavity/oropharynx tissue tolerance in HNSCC patients (41). Whether tumor-
adjacent tissue radioprotectors can be effective in patients with an intrinsic defect in DNA
repair is unknown.
In the present studies, we tested a novel small molecule mitochondrial-targeted GS-nitroxide
(JP4-039) (27, 32, 33) for its radiobiological effect on cells of four Fanconi anemia patient
cell lines. A cell line from a FancD2–/– patient was radiosensitive relative to its transgene-
restored subline. In contrast, a cell line from a patient with the FancG–/– genotype was
relatively radioresistant compared to its transgene-restored subline. Whether this result with
FancG–/– cells represents selection for a secondary mutation during cell line establishment
that confers radioresistance without MMC resistance is unknown. Studies with other
Bernard et al. Page 6













FancG–/– patient cell lines or freshly removed cells may provide additional information. In
both FA cell lines and their transgene-restored subclonal lines, JP4-039 added before or after
irradiation increased radioresistance in clonogenic survival curve assays. Cell lines from two
other patients with the Fanc-A or Fanc-C genotype were similar in radiosensitivity to Fanc-
D2–/– cells and were also protected and mitigated by JP4-039. Fluorophore-labeled JP4-039
(BODIPY) localized to the mitochondria of these cell lines. JP4-039 was more effective at
lower concentrations than Tempol and more effectively preserved cellular antioxidant stores,
further confirming its free radical scavenging. Thus JP4-039 is potentially a valuable
radioprotector for FA patient cells independent of their intrinsic radiosensitivity.
An explanation for the radiosensitivity of the FancD2–/– (PD20F) cell line might be related
to other FA pathway components. In the PD20F (FancD2–/–) cell line, the core complex is
formed but does not monoubiquinate the missing FancD2 protein and thus cannot repair
through its normal pathway, or the associated pathways, to the extent seen in the FancG–/–
(PD326) cell line. This mechanism may explain why the PD20F cell line was more
radiosensitive (ñ was smaller) than the FancG–/– (PD326) cell line. FancD2–/– cells have
greater genetic instability than other FA cells, which may correlate with the higher incidence
of tumors in the mouse model and the reduced numbers of hematopoietic stem and
progenitor cells compared to FancC–/– cells (42). Genome instability in the FancD2–/–
genotype may also contribute to instrinsic radiosensitivity of PD20F cells.
The radioresistance of the FancG–/– (PD326) cell line was unexpected. The FancC protein
presides over the cellular apoptotic threshold by repressing proapoptotic signals. Hsp70
mediates protection from cellular stresses, including radiation, TNF-α and caspase activation
(43–45), binds to hsp70, and prevents apoptosis by suppressing PKR activation (46, 47).
Once activated, PKR phosphorylates the α-subunit of eIF2, a protein synthesis initiation
factor, and thus inhibits translation, upregulates the proapoptotic proteins Bax and Fas, and
induces apoptosis (48). In the FancG–/– (PD326) cells, the FA core complex may not have
formed, and an alternative pathway of FancC binding to hsp70 may have been upregulated,
which may have upregulated hsp70, suppressing PKR (48, 49). Further studies will be
required to explain the relative radioresistance of PD326 cells compared to the transgene-
restored FancG cells.
Ionizing radiation induces reactive oxygen species, which cause lipid peroxidation at the
mitochondrial membrane and initiate a cascade of biochemical events, leading to an increase
in mitochondrial membrane permeability, the release of cytochrome c into the cytoplasm,
and caspase-3 activation, leading to apoptotic death (32). The targeting of JP4-039 to
mitochondria (33) decreases apoptosis and increases radioresistance (32). While JP4-039
and Tempol induced radioresistance, the DNA crosslinking effect of MMC was not altered
in FA cells or transgene-restored sublines (50). These results may reflect a short duration of
action of JP4-039 and Tempol relative to MMC or may indicate that the mechanism of cell
killing by MMC was not altered by antioxidants. MMC-treated cells (50) may have
overwhelmed JP4-039 by ongoing generation of ROS induced by MMC. While Tempol has
been shown to be effective as a tumor inhibitor in one mouse model of Fanconi anemia (51),
Tempol increased the sensitivity of FancD2–/– (PD20F) cells to MMC while JP4-039 did
not. This result emphasizes the potential importance of mitochondrial targeting for a safe
radiation-protective effect in the setting of other chemotherapeutic drugs used in HNSSC
patients.
The present data support the use of an organ-specific radioprotector for the oral cavity in
Fanconi anemia patients and in other patients with genetically determined defects in DNA
repair, including Bloom syndrome and ataxia telangiectasia, who may require external-beam
radiotherapy. Studies with radiosensitive FancD2–/– mice (10) bearing orthotopic tumors are
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in progress using a novel formulation of JP4-039/F15, which has proven successful in
radioprotection of the esophagus (33).
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Sensitivity of FA cell lines to MMC relative to the respective transgene-restored line. Cells
were incubated in the presence of each concentration of MMC for 3 days. Cells were
trypsinized and plated as described in the Methods. At day 8, colonies of ≥50 cells were
stained with crystal violet solution and over 10,000 cells were counted. Panel A: FancG–/–
(PD326) cells were significantly more sensitive to MMC than transgene-restored FancG
cells (P < 0.0001). Panel B: FancD2–/– (PD20F) cells were significantly more sensitive to
MMC than transgene restored FancD2 cells (P < 0.0001).
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JP4-039-BODIPY colocalizes to mitochondria in Fanc-D2 and Fanc-D2–/– (PD20F) cells.
Cells were stained with MitoTracker Red and JP4-039-BODIPY. Panels A and B:
MitoTracker only (red); panels C and D: JP4-039-BODIPY only (green); panels E and F:
JP4-039-BODIPY/MitoTracker colocalization (yellow). Original magnification 1000×.
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JP4-039 does not alter the sensitivity of FA patient cell lines to MMC. Cells of FA patient
cell lines and FA transgene-restored cell lines were incubated in each concentration of MMC
for 3 days. JP4-039 or Tempol (10 μM) was added daily starting 1 h before initial
incubation, then daily for 7 days. Cells were trypsinized and replated at day 3 and then after
8 days were stained with crystal violet solution and colonies of ≥50 cells counted. Panel A:
Neither JP4-039 nor Tempol altered the sensitivity of FancG transgene-restored cells to
MMC (P = 0.6 and 0.1, respectively). Panel B: Neither JP4-039 or Tempol altered the
sensitivity of FancG–/– (PD326) cells to MMC (P = 0.71 and 0.58,=respectively). Panel C:
JP4-039 did not alter the sensitivity of FancD2 restored cells to MMC (P = 0.4); however,
Tempol increased the sensitivity to MMC (P = 0.005). Panel D: JP4-039 did not alter the
sensitivity of FancD2 transgene-restored cells (P =1.0) while Tempol increased the
sensitivity to MMC (P = 0.04).
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Decreased radiation induced DNA strand breaks by comet assay correlates with relative
radioresistance of Fanc-G–/– (PD326) cells compared to Fanc-D2–/– (PD20F) cells. Cells
were irradiated to 0 or 6 Gy and collected 10 min after irradiation. The cells were prepared
for the neutral comet assay, which measured double-stranded DNA breaks by plating in low-
melt agarose, then treated with protease and RNase to leave the DNA only. The DNA was
electrophoresed and stained with a fluorescent dye as described in the Methods. The tail
intensity was determined, with a higher tail intensity indicating increased DNA strand
breaks. The Fanconi anemia cell line comet intensity was compared for eight groups (Fanc-
D2 0 Gy, Fanc-D2 6 Gy, Fanc-G 0 Gy, Fanc-G 6 Gy, PD326 0 Gy, PD326 6 Gy, PD20F 0
Gy, PD20F 6 Gy). Because there were multiple 0 values in some of the groups, and because
the test for normality was rejected for most of the groups, the two-sided Wilcoxon rank sum
test was used to test the difference between any two groups. Data were summarized by
median and interquartile range (IQR) correspondingly. In each group, data are restated as
median, interquartile range (IQR), and sample size (n). P values were calculated for the
comparison between any two groups with the two-sided Wilcoxon rank sum test. For all
tests, P values of less than 0.05 were regarded as significant. All the tests had significant P
values except the one comparing PD326 and Fanc-G cells at 0 Gy. Fanc-D2–/– (PD20F)
cells had more DNA strand breaks (comet intensity) than Fanc-G–/– (PD326) cells (P <
0.0001). Gene-corrected Fanc-D2 cells and Fanc-G cells were more radioresistant or
radiosensitive than parent lines (P < 0.0001), consistent with clonogenic survival curve data.
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TABLE 1
Effect of GS-Nitroxide JP4-039 Added before or after Irradiation on the Radiosensitivity of Fanconi Anemia
D2–/– and G–/– Cell Lines
Cell line D0 (Gy) ñ
FancG –/– (PD326) 1.2 ± 0.3 9.4 ± 1.5
P = 0.001* (compared to FancG)
Tempol + PD326 before 1.2 ± 0.1 14.7 ± 1.4
P = 0.01* (compared to PD326)
JP4-039 + PD326 before 1.1 ± 0.2 20.5 ± 4.5
P = 0.02* (compared to PD326)
P = 0.001* (compared to PD326 + Tempol)
PD326 + Tempol after 1.1 ± 0.1 14.8 ± 1.5
P = 0.01* (compared to PD326)
P = 0.001* (compared to FancG + Tempol)
PD326 + JP4-039 after 1.1 ± 0.1 20.5 ± 4.5
P = 0.02* (compared to PD326)
P = 0.03* (compared to FancG +J P4-039)
FancG restored 1.2 ± 0.1 2.2 ± 0.5
Tempol + FancG before 1.3 ± 0.2 7.2 ± 0.7
P = 0.001* (compared to FancG)
JP4-039 + FancG before 1.3 ± 0.1 20.5 ± 4.5
P = 0.002* (compared to FancG)
FancG + Tempol after 1.0 ± 0.2 7.2 ± 0.7
P = 0.001* (compared to FancG)
FancG + JP4-039 after 1.1 ± 0.1 6.8 ± 0.6
P = 0.001* (compared to FancG)
FancD2 –/– (PD20F) 1.4 6 0.2 2.0 ± 0.7
P = 0.03* (compared to FancD2)
Tempol + PD20F before 1.5 ± 0.3 4.5 ± 1.8
P = 0.02* (compared to PD320F)
JP4-039 + PD20F before 1.7 ± 0.1
P = 0.04* (compared to PD320F)
1.9 ± 0.3
PD20F + Tempol after 1.5 ± 0.3 4.0 ± 1.1
PD20F + JP4-039 after 1.6 ± 0.3 6.2 ± 0.7
P = 0.01* (compared to PD20F)
FancD2 restored 1.0 ± 0.1 4.7 ± 2.2
Tempol + FancD2 before 1.1 ± 0.1
P = 0.06* (compared to Tempol + PD20F)
5.1 ± 1.0
JP4-039 + FancD2 before 1.1 ± 0.1
P = 0.0009* (compared to JP4-039 + PD20F)
7.6 ± 0.6
P < 0.0001* (compared to JP4-039 + PD20F)
P = 0.04* (compared to FancD2)
FancD2 + Tempol Post 1.2 ± 0.1 4.7 ± 1.2
FancD2 + JP4-039 Post 1.2 ± 0.1 7.8 ± 0.5
P = 0.02* (compared to FancD2)
Notes. FancG, FancG –/– (PD326), FancD2 and FancD2–/– (PD20F) cells were irradiated with 0 to 8 Gy. The cells were plated in 4-well tissue
culture plates and incubated in a high CO2 incubator for 8 days, and colonies of greater than 50 cells were counted. The data were analyzed by the
linear-quadratic and single-hit, multitarget models; the D0 and ñ are shown. FancG transgene-restored cells were more radiosensitive than
FancG–/– cells [decreased shoulder on the survival curve (ñ)], while FancD2–/– cells were more radiosensitive than transgene-restored FancD2
cells. The data are the average of three separate experiments on 3 separate days. Tempol or JP4-039 was added before or after irradiation and the
D0 and ñ for each cell line were calculated as described in the Methods. Means ± SD of D0 and ñ in each group are shown. P values were
calculated for the comparison between two groups with the two-sided two-sample t test. Significant P values are indicated by an asterisk. Each
experiment was carried out a minimum of three times.
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TABLE 2
Effect of GS-Nitroxide, JP4-039 Added before or after Irradiation on the Radiosensitivity of Fanconi Anemia
A and C Patient Cells
Cell line D0 (Gy) ñ
Fanc-A–/– (OH-SU-974) 1.6 ± 0.1 4.2 ± 1.1
Tempol (10 μM) + Fanc-A–/– before 2.5 ± 0.2
(P = 0.007)
3.2 ± 1.3
JP4-039 (10 μM) + Fanc-A–/– before 1.9 ± 0.1
(P = 0.02)
4.3 ± 0.6
Fanc-A–/– + Tempol after 2.1 ± 0.1
(P = 0.02)
3.5 ± 1.5
Fanc-A–/– + JP4-039 after 2.1 ± 0.1
(P = 0.002)
2.2 ± 0.7
Fanc-C–/– (VU-113) 1.6 ± 0.1 3.3 ± 0.3
Tempol (10 μM) + Fanc-C–/– before 1.9 ± 0.1
(P = 0.003)
2.4 ± 0.2
JP4-039 (10 μM) + Fanc-C–/– before 2.3 ± 0.2
(P = 0.02)
2.4 ± 1.0
Fanc-C–/– + Tempol after 1.6 ± 0.2 10.3 ± 1.0
(P = 0.003)
Fanc-C–/– + JP4-039 after 1.5 ± 0.2 8.5 ± 1.1
(P = 0.01)













Bernard et al. Page 17
TABLE 3
JP4-039 is More Effective than Tempol in Radioprotective Capacity
Cell line Concentration (μM) ñ
FancG 0 2.5 ± 0.3
Tempol + FancG 0.1 4.5 ± 1.3
1 4.9 ± 0.9
10 7.2 ± 0.7
(P = 0.001)
JP4-039 + FancG 0.1 4.0 ± 0.1
(P = 0.04)
1 5.3 ± 0.1
(P = 0.01)
10 20.5 ± 4.5
(P = 0.002)
Notes. FancG cells were preincubated in 0, 0.1, 1.0 or 10 μM tempol or JP4-039 for 1 h and then irradiated with 0–8 Gy as described in the
Methods. Colonies were stained with crystal violet 7 days later, and colonies of greater than 50 cells were counted. The data were analyzed by
linear-quadratic and single-hit, multitarget models. At 0.1, 1 and 10 μM, the cells incubated with JP4-039 had a significantly increased ñ compared
to cells treated with the same molar concentration of Tempol. At 0.1 or 1.0 μM, Tempol was not radioprotective. The mitochondrial localization of
JP4-039 was >10-fold more effective than Tempol by molar concentration.
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TABLE 4
JP4-039-BODIPY is as Effective a Radioprotector of Fanc-D2 Cells as JP4-039
Condition D0 (Gy)
FancD2 control 1.0 ± 0.1
DMSO + FancD2 1.0 ± 0.1
Tempol + FancD2 1.1 ± 0.1
JP4-039 + FancD2 1.1 ± 0.1
(P = 0.003)
JP4-039-Bodipy + FancD2 1.1 ± 0.1
(P < 0.0001)
Notes. FancD2 cells were incubated for 1 h in DMSO (control), tempol (10 μM), JP4-039 (10 μM) or JP4-039-Bodipy (10 μM), then irradiated with
0 to 8 Gy, plated in 4-well tissue culture plates, incubated for 7 days at 37°C in a CO2 incubator, and stained with crystal violet. Colonies of greater
than 50 cells were counted as described in the Methods. Data were analyzed using linear-quadratic or single-hit, multitarget models. FancD2 cells
treated with JP4-039 or JP4-039-BODIPY had significantly increased survival compared to control irradiated FancD2 cells. There was no
significant difference between JP4-039 and JP4-039-BODIPY.
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